Dr. Jeffrey Lawson named chief scientific officer of VarmX

VarmX, a biotechnology company focused on the development of therapies to reverse blood coagulation, named Jeffery Lawson, MD, PhD, its chief scientific officer. 

Advertisement

Dr. Lawson most recently served as president and CEO of Humacyte, a regenerative medicine company, according to a March 8 news release from VarmX. He previously served as director of clinical trials for the department of surgery at Duke University Medical Center in Durham, N.C. 

Dr. Lawson is succeeding Pieter Reitsma, PhD, founder of VarmX, who will serve as special adviser to the company’s board, the release said.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Leadership

Advertisement

Comments are closed.